Round 3: For TTFields vs Against TTFields
The third round tackles one of the most novel and debated modalities: Tumor Treating Fields (TTFs). The panel evaluates the clinical evidence, mechanistic rationale, and practical considerations behind integrating TTFs into metastatic NSCLC management. Panelists highlight promising survival data and the potential for synergy with existing treatments, along with logistical considerations for patients.
To hear arguments related to immunotherapy vs alternative therapy, see Round 1.
To hear arguments related to adding radiation therapy or switching treatments, see Round 2.
Transcript coming soon!
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
